(Q36730674)

15 August 2017

1 reference

title

Emerging treatments for major depression (English)

1 reference

15 August 2017

Trevor R Norman

1

1 reference

15 August 2017

Graham D Burrows

series ordinal

2

1 reference

15 August 2017

publication date

1 February 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

203-213

1 reference

Treatment of mood disorders

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Novel naphthalenic ligands with high affinity for the melatonin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Effect of agomelatine in the chronic mild stress model of depression in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Sleep disturbances and depression: a challenge for antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Pramipexole for bipolar II depression: a placebo-controlled proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Pramipexole in treatment-resistant depression: a 16-week naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Pramipexole in treatment-resistant depression: an extended follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Dual action antidepressants and some important considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Acute administration of the novel serotonin and noradrenaline reuptake inhibitor, S33005, markedly modifies sleep-wake cycle architecture in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Depressive psychomotor disturbance, cortisol, and dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

The role of corticotropin-releasing factor in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Elevated Concentrations of CSF Corticotropin-Releasing Factor-Like Immunoreactivity in Depressed Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Future therapeutic targets in mood disorders: the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Anxiolytic-like effects of the corticotropin-releasing factor1 (CRF1) antagonist DMP904 [4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine] administered acutely or chronically at doses occupying central CRF1 rec

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Vasopressin in affective illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Plasma levels of arginine vasopressin elevated in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Anxious-retarded depression: relation with plasma vasopressin and cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

The central vasopressinergic system: examining the opportunities for psychiatric drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

The vasopressin V1b receptor as a therapeutic target in stress-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Antidepressants for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Modulation of glutamate receptors: strategies for the development of novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Neuropeptide Y (NPY) and depression: from animal studies to the human condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

A role for melanin-concentrating hormone in the central regulation of feeding behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Molecular characterization of the melanin-concentrating-hormone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Depression: a case of neuronal life and death?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Antidepressant-like effect of brain-derived neurotrophic factor (BDNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

Third-generation antidepressants: do they offer advantages over the SSRIs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.2.203

21 January 2018

Identifiers

DOI

10.1586/14737175.7.2.203

1 reference

15 August 2017

1 reference